Thrombotic microangiopathy in a patient with systemic lupus erythematosus and systemic sclerosis overlap syndrome: a case report
This case report describes a 32-year-old woman with systemic lupus erythematosus and systemic sclerosis overlap syndrome who was successfully treated for immune-mediated thrombotic thrombocytopenic purpura (iTTP) following a complex diagnostic process that utilized the PLASMIC score, ADAMTS13 testing, and the systematic exclusion of other thrombotic microangiopathies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the body's vast network of tiny blood vessels, a delicate balance keeps blood flowing smoothly to every organ. This system relies on a specific protein that acts like a molecular scissors, cutting long, sticky strands of a clotting factor called von Willebrand factor into manageable pieces. When this protein works correctly, blood flows freely. However, in a rare and dangerous condition known as immune-mediated thrombotic thrombocytopenic purpura, the body's own immune system mistakenly creates antibodies that attack and disable this molecular scissors. Without this cutting action, the long strands accumulate and trap platelets, forming microscopic clots that clog the smallest vessels. These clots shred red blood cells as they pass through, causing severe anemia, and starve organs of oxygen, leading to potential organ failure or death. While this condition can strike anyone, it becomes even more complex to diagnose when it occurs in patients who already suffer from autoimmune diseases, where the immune system is already prone to confusion.
A team of doctors recently documented the case of a thirty-two-year-old woman who arrived at the emergency room with a severe headache, nausea, and abdominal pain. She had a known history of two overlapping autoimmune conditions: systemic lupus erythematosus and systemic sclerosis. For over a year, she had not been taking her prescribed medications, leaving her immune system unchecked. Upon examination, her blood work revealed a terrifying picture: her platelet count was critically low, her red blood cells were being destroyed, and her kidneys were under stress. The medical team faced a difficult puzzle. In patients with her specific background, low platelets and blood cell destruction could stem from several different causes, each requiring a completely different treatment. One possibility was a sudden crisis in her scleroderma affecting the kidneys, which would require aggressive blood pressure management. Another was a catastrophic reaction to antibodies that cause clots everywhere, which would demand blood thinners. Yet another was a drug reaction or an infection. Giving the wrong treatment could be fatal; for instance, blood thinners used for one condition would be disastrous for the other.
To solve this, the doctors used a clinical scoring system designed to estimate the likelihood of the missing molecular scissors before the specific test results returned. The patient's score placed her in the highest risk category, suggesting she was suffering from the rare condition where the scissors are disabled. Acting on this high probability, the medical team immediately began a life-saving procedure called therapeutic plasma exchange. This process filters the patient's blood to remove the harmful antibodies and replace them with healthy plasma containing the missing protein. Simultaneously, they administered high-dose steroids to calm the immune system. While these treatments were underway, the team systematically ruled out every other possibility. They confirmed her blood pressure was normal, her kidney function was preserved, and she had no signs of the specific antibodies associated with kidney crises or catastrophic clotting. They also confirmed she was not pregnant and had no signs of a severe infection or blood clotting disorder.
The definitive answer arrived six days after her admission, when the laboratory confirmed that her molecular scissors were indeed almost completely absent, with activity levels dropping below three percent of normal. A follow-up test found a high level of antibodies actively blocking the protein, confirming the diagnosis of immune-mediated thrombotic thrombocytopenic purpura. With the diagnosis secured, the team added a newer medication that works by preventing the sticky strands from clumping with platelets, offering an extra layer of protection while the immune system was reset. Over the next twelve days, the patient's condition improved dramatically. Her platelet count rebounded from a dangerously low level to a robust number, the markers of blood cell destruction returned to normal, and her headache resolved. She was discharged with a plan to continue medication to prevent the immune system from attacking the protein again, including a treatment that targets the specific cells responsible for making the harmful antibodies.
This case highlights the critical importance of recognizing that autoimmune diseases can sometimes trigger other rare, life-threatening conditions. It demonstrates that when a patient with a complex immune history presents with signs of blood vessel blockage, doctors must move quickly to distinguish between several dangerous possibilities. The successful outcome relied on a systematic approach: using a risk score to start treatment immediately, rigorously excluding other causes that would require different therapies, and confirming the specific lack of the molecular scissors to guide the final course of care. The patient's recovery underscores that even in the face of overlapping and confusing autoimmune disorders, precise diagnosis and a combination of modern therapies can restore health and prevent tragedy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.